Therapy News and Research

RSS

PCSK9 inhibitor can reduce need for apheresis treatment in patients with familial hypercholesterolemia

Patients who have heterozygous familial hypercholesterolemia (HeFH), a condition that causes abnormally raised low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease, can significantly reduce or even eliminate their need for expensive and time-consuming apheresis treatments with the PCSK9 inhibitor alirocumab.

29 Aug 2016

Large cardiopoietic regenerative therapy trial for patients with congestive heart failure reveals new insights

A therapy that uses bone-marrow stem cells to promote heart repair did not significantly improve the primary outcome over a sham procedure among patients with congestive heart failure.

29 Aug 2016

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.

29 Aug 2016

Study results confirm safety and efficacy of INSIGHTEC’s Exablate Neuro system for the treatment of essential tremor

INSIGHTEC, the leader in MR-guided Focused Ultrasound (MRgFUS) therapy, has announced that the New England Journal of Medicine (NEJM) has published the results of a pivotal study of their Exablate Neuro system for the non-invasive treatment of essential tremor (ET). The study met its primary endpoint with patients treated with Exablate Neuro demonstrating a clinically significant 47% improvement in a composite tremor score at three months as compared to no change in the sham cohort.

29 Aug 2016

NEJM publishes MINDACT trial results

Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the peer-reviewed publication of the primary outcome results of the Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy (MINDACT) clinical trial in the prestigious New England Journal of Medicine (NEJM). (i, iii, iv) The publication demonstrates that 46% of breast cancer patients considered for chemotherapy, whose tumors are classified MammaPrint Low Risk, have excellent survival without chemotherapy, and can thus be candidates to avoid this toxic therapy.

29 Aug 2016

Study shows non-inferiority of short-term dual antiplatelet therapy in patients with DES placement

A short-term course of dual antiplatelet therapy (DAPT) is non-inferior to a longer course in patients who have undergone placement of a particular kind of drug-eluting stent (DES), researchers reported here.

29 Aug 2016

Engineered gut bacteria may one day help reduce negative health effects of obesity

A new therapy that involves engineered gut bacteria may one day help reduce the health problems that come with obesity. Incorporating the engineered bacteria into the guts of mice both kept them from gaining weight and protected them against some of the negative health effects of obesity.

28 Aug 2016

Alcohol-related hospitalisation linked to increased risk of ischaemic stroke in atrial fibrillation patients

Alcohol related hospitalisation is associated with a doubled risk of ischaemic stroke risk in patients with non-valvular atrial fibrillation, according to a study presented at ESC Congress 2016 today by Dr Faris Al-Khalili, cardiologist, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.

28 Aug 2016

Direct catheter-based thrombectomy equally effective to bridging thrombolysis in acute ischaemic stroke

Direct catheter-based thrombectomy is equally effective to bridging thrombolysis in the treatment of acute ischaemic stroke, according to results from the observational PRAGUE-16 registry study presented at ESC Congress 2016 today.

28 Aug 2016

ESC releases novel position paper on tackling cardiotoxicity of anticancer treatments

The European Society of Cardiology has launched a novel position paper, under the auspices of its Committee for Practice Guidelines, on tackling the cardiac toxicity of anticancer therapies. The cardio-oncology paper is published online today in European Heart Journal and on the ESC Website.

27 Aug 2016

MRI-guided focused ultrasound treatment improves quality of life in patients with essential tremor

Treatment with MRI-guided focused ultrasound significantly improves tremors and quality of life in patients with essential tremor (ET), the most common movement disorder, according to a study published in the August 25 issue of the New England Journal of Medicine.

27 Aug 2016

First ESC Guidelines on Atrial Fibrillation published online

The first European Society of Cardiology (ESC) Guidelines on Atrial Fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) are published online today in European Heart Journal and the European Journal of Cardio-Thoracic Surgery, and on the ESC Website.

27 Aug 2016

Newly-developed epigenetic test can be used to identify tumors responsible for metastasis in cancer patient

In patients with cancer, initial diagnosis most often includes the detection of the primary or original tumor and the presence or absence of metastases, ie cells from the original tumor that have escaped from their original location and are growing into other tissues of the patient.

27 Aug 2016

BirchBioMed announces successful completion of Phase I trial for topical treatment to prevent scarring

BirchBioMed Inc. announced today that a unique and ground-breaking topical treatment developed by University of British Columbia researchers to prevent scarring has completed a Health Canada approved Phase I trial.

27 Aug 2016

Can-Fite BioPharma reports financial results, provides update on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2016 and updates on its drug development programs.

27 Aug 2016

New drug delivery system slows and controls tumors not aiming for complete elimination

Researchers have created a new drug delivery system that could improve the effectiveness of an emerging concept in cancer treatment - to dramatically slow and control tumors on a long-term, sustained basis, not necessarily aiming for their complete elimination.

26 Aug 2016

Therapy News and Research

PCSK9 inhibitor can reduce need for apheresis treatment in patients with familial hypercholesterolemia

Large cardiopoietic regenerative therapy trial for patients with congestive heart failure reveals new insights

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Study results confirm safety and efficacy of INSIGHTEC’s Exablate Neuro system for the treatment of essential tremor

NEJM publishes MINDACT trial results

Study shows non-inferiority of short-term dual antiplatelet therapy in patients with DES placement

Engineered gut bacteria may one day help reduce negative health effects of obesity

Alcohol-related hospitalisation linked to increased risk of ischaemic stroke in atrial fibrillation patients

Direct catheter-based thrombectomy equally effective to bridging thrombolysis in acute ischaemic stroke

ESC releases novel position paper on tackling cardiotoxicity of anticancer treatments

MRI-guided focused ultrasound treatment improves quality of life in patients with essential tremor

First ESC Guidelines on Atrial Fibrillation published online

Newly-developed epigenetic test can be used to identify tumors responsible for metastasis in cancer patient

BirchBioMed announces successful completion of Phase I trial for topical treatment to prevent scarring

Can-Fite BioPharma reports financial results, provides update on drug development programs

New drug delivery system slows and controls tumors not aiming for complete elimination

Kobe University researchers develop new technique for high-level genome editing operation

Novel small-molecule Wnt inhibitor may provide new treatment option for colorectal cancer patients

Philips to showcase advanced cardiology solutions at ESC Congress 2016

Study finds age-dependent differences in expression of allergy to dust mites

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News